Poster Presentations Session I
Poster Presentations Session I Saturday, 16 September 2017
POSTERS SET-UP: 8:15 - 8:30
POSTERS DISPLAY HOURS: 8:30 - 20:00
POSTER AUTHOR DISCUSSION: 18:30 - 19:30
POSTERS DISMANTLE: 20:00


Poster display locations are shown below the poster codes
SYSTEMIC DISORDERS/CONDITIONS - Clinical Outcomes Studies
PSY1
WITHDRAWN

PSY2
J16
SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF AMFEPRAMONE AND MAZINDOL AS A MONOTHERAPY FOR THE TREATMENT OF OBESE OR OVERWEIGHT PATIENTS
Lucchetta R1, Riveros B1, Pontarolo R1, Radominski R1, Otuki M1, Fernandez-Llimos F2, Correr C1
1Federal University of Parana, Curitiba, Brazil, 2Universidade de Lisboa, Lisboa, Portugal

PSY3
K1
MEDICAL TREATMENTS FOR ACROMEGALY: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Leonart LP, Ferreira VL, Tonin FS, Pontarolo R
Universidade Federal do Paraná, Curitiba, Brazil

PSY4
K2
ASSOCIATION BETWEEN SECOND-LINE THERAPY (2LT) REGIMEN TYPE, DURATION OF THERAPY (DOT), AND TIME TO NEXT TREATMENT (TTNT) IN A UNITED STATES (US) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) COHORT: AN ELECTRONIC MEDICAL RECORDS (EMR)-BASED STUDY
Romanus D1, Raju A2, Yong C1, Farrelly E2, Luptakova K1, Labotka R1, Noga SJ1, Blazer M2, Hari P3
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 2Xcenda, LLC, Palm Harbor, FL, USA, 3Medical College of Wisconsin, Division of Hematology Oncology, Milwaukee, WI, USA

PSY5
K3
USE OF THALIDOMIDE IN ERYTHEMATOSUS LUPUS TREATMENT
Teixeira DR1, Galdino-Pitta MR1, Nunes TR2, Viana DC3, Araujo BC2, Zanghelini F4, Pereira MC2, Rego MJ4, Oliveira MD5, Pitta Id4, Pitta MG2, Andrade CA2
1Federal University of Pernambuco, Recife, Brazil, 2Universidade Federal de Pernambuco, Recife, Brazil, 3Avenida Professor Moraes Rego, Recife, Brazil, 4UFPE, Recife, Brazil, 5University Federal de Pernambuco, Recife, Brazil

PSY6
K4
TREATMENT PATTERNS AND IMPACT OF NOT ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS IN LATIN AMERICA
Papadimitropoulos M1, Romiti R2, Garcia EG3, Lobosco S4, Leonardi Reyes F5, Wang X6, Haynes G7
1Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, 2Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil, 3Elil Lilly and Co, Mexico City, Mexico, 4Adelphi Real World, Macclesfield, UK, 5Eli Lilly, Bogota, Colombia, 6University of Toronto, Toronto, ON, Canada, 7Eli Lilly and Company, Indianapolis, IN, USA

PSY7
K5
CHARACTERISTICS OF LATIN AMERICAN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADVANCED THERAPY
Brnabic A1, Xavier R2, Goncalves L3, Lucas J4, Hernandez P5, Gaich CL6, Papadimitropoulos M7
1Eli Lilly and Company, Sydney, Australia, 2Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Eli Lilly and Company, São Paulo, Brazil, 4Adelphi Real World, Bollington, UK, 5Compañía Farmacéutica Eli Lilly de Centroamérica, S.A, Este San José, Costa Rica, 6Eli Lilly and Company, Indianapolis, IN, USA, 7Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada

PSY8
K6
CHARACTERISTICS OF PSORIASIS PATIENTS IN LATIN AMERICA
Burge R1, Galimberti R2, Goncalves L3, Lucas J4, Wang X5, Botello BS6, Brnabic A7
1Eli Lilly and Company, Indianapolis, USA; Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH, USA, 2Universidad de Buenos Aires, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Eli Lilly and Company, São Paulo, Brazil, 4Adelphi Real World, Bollington, UK, 5University of Toronto, Toronto, ON, Canada, 6Eli Lilly and Company, Mexico City, Mexico, 7Eli Lilly and Company, Sydney, Australia

PSY9
K7
BURDEN OF DISEASE FOR PSORIASIS IN ARGENTINA, BRAZIL, COLOMBIA AND MEXICO
Papadimitropoulos M1, Romiti R2, Guerra MA3, Vorstenbosch E4, Brnabic A5, Haynes G6, Goncalves L7, Leonardi Reyes F8, Garcia EG9, Burge R10
1Eli Lilly and Company, Canada; University of Toronto, Toronto, ON, Canada, 2Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil, 3Monterrey, Nuevo Leon, Mexico, 4Parc Sanitari Sant Joan de Deu, Barcelona, Spain, 5Eli Lilly and Company, Sydney, Australia, 6Eli Lilly and Company, Indianapolis, IN, USA, 7Eli Lilly and Company, São Paulo, Brazil, 8Eli Lilly, Bogota, Colombia, 9Elil Lilly and Co, Mexico City, Mexico, 10Eli Lilly and Company, Indianapolis, USA; Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH, USA

PSY10
K8
TREATMENT PATTERNS AND SATISFACTION FOR RHEUMATOID ARTHRITIS PATIENTS IN LATIN AMERICA UNDERGOING ADVANCED THERAPY
Papadimitropoulos M1, Mysler E2, Garcia EG3, Lobosco S4, Botello BS5, Leonardi Reyes F6, Haynes G7
1Eli Lilly and Company, Canada; University of Toronto, Toronto, ON, Canada, 2Reumatología, Organización Médica de Investigación, Buenos Aires, Argentina, 3Elil Lilly and Co, Mexico City, Mexico, 4Adelphi Real World, Macclesfield, UK, 5Eli Lilly and Company, Mexico City, Mexico, 6Eli Lilly, Bogota, Colombia, 7Eli Lilly and Company, Indianapolis, IN, USA

SYSTEMIC DISORDERS/CONDITIONS - Cost Studies
PSY11
K9
BUDGET IMPACT OF INTRODUCING SECUKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
Suzuki C, Lopes N
Novartis Biociências SA, Sao Paulo, Brazil

PSY12
K10
BUDGET IMPACT OF THE INCLUSION OF OXYCODONE IN THE BRAZILIAN PUBLIC HEALTHCARE SETTING FOR THE TREATMENT OF CANCER PAIN
Souza DA1, Aguiar EC1, Miguel AK2, Rosim RP2, Ballalai Ferraz AF2
1Mundipharma, São Paulo, Brazil, 2QuintilesIMS, São Paulo, Brazil

PSY13
K11
AN OBSERVATIONAL RETROSPECTIVE COHORT DATABASE STUDY TO ESTIMATE COSTS REGARDING IMMUNOGLOBULIN USE FOR ITP TREATMENT IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
Figueiredo AC1, dos Santos RF2, Manfrin DF2, Lemos M3
1Amgen, sao paulo, Brazil, 2Amgen, São Paulo, Brazil, 3Amgen, São Paulo, Brazil

PSY14
K12
REAL-WORLD HEALTH CARE EXPENDITURE IN HEMOPHILIA A PATIENTS USING STANDARD AND EXTENDED HALF-LIFE RECOMBINANT FACTOR VIII PRODUCTS
Chhabra A1, Tortella BJ2, Alvir J1, Estevez C2, Spurden D3, Hodge J1, McDonald M1, Pleil A4
1Pfizer Inc, New York, NY, USA, 2Pfizer Inc, Collegeville, PA, USA, 3Pfizer Limited, Surrey, UK, 4Pfizer Inc, San Diego, CA, USA

PSY15
K13
BURDEN OF DISEASE FOR RHEUMATOID ARTHRITIS IN ARGENTINA, BRAZIL, COLOMBIA, MEXICO AND VENEZUELA
Papadimitropoulos M1, Castelar G2, Brnabic A3, Vorstenbosch EC4, Garcia EG5, Botello BS5, Hernandez P6, Goncalves L7, Gaich CL8
1Eli Lilly and Company, Canada; University of Toronto, Toronto, ON, Canada, 2Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, 3Eli Lilly and Company, Sydney, Australia, 4Parc Sanitari Sant Joan de Deu, Barcelona, Spain, 5Eli Lilly and Company, Mexico City, Mexico, 6Compañía Farmacéutica Eli Lilly de Centroamérica, S.A, Este San José, Costa Rica, 7Eli Lilly and Company, São Paulo, Brazil, 8Eli Lilly and Company, Indianapolis, IN, USA

PSY16
K14
IDIOPATHIC PULMONARY FIBROSIS: WHERE THE FUNCTIONAL HEALTH DETERIORATION AND THE HIGH ECONOMIC IMPACT ARE INSEPARABLE. CHALLENGES IN A LATIN AMERICAN COUNTRY
Moreno-Silva NA, Diaz-Toro YR
Productos Roche S.A. Colombia, Bogotá, Colombia

PSY17
K15
DIRECT COSTS OF HEALTH CARE OF CYSTIC FIBROSIS, THE CASE OF A HEALTH INSURER IN COLOMBIA.
Hoyos-Beltrán FJ1, Guarin NE1, Moreno JA1, Muñoz-Galindo IM1, Arevalo HO1, Diaz JA2
1Salud Total EPS, Bogotá D.C., Colombia, 2Universidad Nacional de Colombia, Bogotá D.C., Colombia

PSY18
K16
ANTIBIOTICS TREATMENT PATTERNS AS A COSTS AND RESOURCE UTILIZATION PREDICTOR AMONG PATIENTS SUBMITTED TO BARIATRIC SURGERY: ANALYSIS OF A LARGE HEALTH INSURANCE CLAIMS DATABASE
Luque A, Junqueira Junior SM, Oliveira D, Oliveira FM
Johnson & Johnson Medical Brazil, São Paulo, Brazil

PSY19
K17
PUBLIC HEALTH EXPENDITURE IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA IN MEXICAN INSTITUTIONS
Herrera M1, Salazar A2, Aguirre A3, Fritz K3
1Janssen, Mexico City, Mexico, 2Janssen Mexico, Mexico City, IL, USA, 3Janssen Mexico, Mexico City, Mexico

PSY20
K18
CUSTO DE TRATAMENTO BIOLÓGICO EM PACIENTES COM DOENÇAS REUMÁTICAS EM UMA OPERADORA DE SAÚDE DE FORTALEZA/CE
Neto Vd, Barroso FD, Albuquerque IM, Vieira JB, Sartori DP, Romero JF, Viana A, Junior AN, Rodrigues EX
UNIMED Fortaleza, Fortaleza, Brazil

PSY21
L1
TREATMENT COST COMPARISON OF PIRFENIDONE VERSUS NINTEDANIB ON THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Ho R, Rufino C, Lisondo C, Alves M
Roche Brazil, São Paulo, Brazil

PSY22
L2
ECONOMIC EVALUATION OF ROMIPLOSTIM VS ELTROMBOPAG IN THE TREATMENT OF ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA IN MEXICO
Naranjo M1, Alva ME1, Carlos F2
1Amgen, Mexico City, Mexico, 2R A C Salud Consultores S.A. de C.V, Mexico City, Mexico

PSY23
L3
ESTUDOS ECONÔMICOS DE BELIMUMABE NO TRATAMENTO DO LÚPUS ERITEMATOSO SISTÊMICO - UMA REVISÃO SISTEMÁTICA
Salgado JB1, Santos FM1, Lamarão FR2, Saturnino LT1
1GlaxoSmithkline, Rio de Janeiro, Brazil, 2GlaxoSmithKline, Rio de Janeiro, Brazil

PSY24
L4
COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE VERSUS NINTEDANIB ON THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Ho R, Rufino C, Lisondo C, Alves M
Roche Brazil, São Paulo, Brazil

PSY25
L5
COSTO-EFECTIVIDAD DE LA CIRUGÍA BARIÁTRICA EN COLOMBIA
Gil-Rojas Y1, Lasalvia P1, Hernández F2, Garzón A3, Andrade PC4, Rosselli D3
1Pontificia Universidad Javeriana, Bogota, Colombia, 2NeuroEconomix, Bogota, Colombia, 3Pontificia Universidad Javeriana, Bogotá, Colombia, 4Johnson & Johnson Medical, Bogotá, Colombia

PSY26
L6
THE COST EFFECTIVENESS OF OXYCODONE IN PATIENTS WHO DO NOT RESPOND TO MORPHINE FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE
Souza DA1, Aguiar EC1, Miguel AK2, Rosim RP2, Ballalai Ferraz AF2
1Mundipharma, São Paulo, Brazil, 2QuintilesIMS, São Paulo, Brazil

PSY27
L7
WITHDRAWN

PSY28
L8
COST-MINIMIZATION OF ADALIMUMAB AND INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS REFRACTORY TO CONVENTIONAL THERAPY
Jones K1, Rivera Hurtado R2, Ruet E2, Chaves L3, Izquierdo C3, Monroy Cruz B1, Gay Molina JG4, Gonzalez Godinez I4
1ti Salud, Mexico City, Mexico, 2Abbvie, Mexico City, Mexico, 3AbbVie Inc., North Chicago, IL, USA, 4T.I. Salud, Mexico D.F., Mexico

PSY29
L9
ESTUDIO DE COSTO EFECTIVIDAD DEL FACTOR DE COAGULACIÓN RECOMBINANTE VIII UNIDO A PROTEINA FC PARA EL TRATAMIENTO DE LA HEMOFILIA A EN CHILE
Vargas C1, Balmaceda C1, Rodriguez F2, Rojas R1, Espinoza MA3
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Universidad San Sebastián, Santiago, Chile, 3e Investigador Visitante Honorario, Centro para la Economía de Salud, Universidad de York, York, UK

PSY30
L10
COST-UTILITY ANALYSIS OF TAPENTADOL PROLONGED RELEASE VERSUS OXYCODONE CONTROLLED RELEASE IN THE FIRST-LINE TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN UNDER THE PERSPECTIVE OF THE COLOMBIAN SUBSIDIZED PUBLIC HEALTHCARE SYSTEM
Lemmer T1, Piedade A1, Engel T1, Sales L1, Martinez C2, Marcondes L2, Fernandez D3, Rojas S3, Mojica C3, Velasquez C3, Bustos J3, Arteaga A2
1Evidências - Kantar Health, São Paulo, Brazil, 2Grünenthal, Ciudad de México, Mexico, 3Grünenthal, Bogotá, Colombia

PSY31
L11
ESTUDIO DE COSTO EFECTIVIDAD DEL FACTOR DE COAGULACIÓN RECOMBINANTE IX UNIDO A PROTEINA FC PARA EL TRATAMIENTO DE LA HEMOFILIA B EN CHILE
Balmaceda C1, Vargas C1, Rodriguez F2, Rojas R1, Espinoza MA3
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Universidad San Sebastián, Santiago, Chile, 3e Investigador Visitante Honorario, Centro para la Economía de Salud, Universidad de York, York, UK

PSY32
WITHDRAWN

SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes & Patient Preference Studies
PSY33
L12
HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE PLAQUE PSORIASIS PATIENTS IN BRAZIL
Lopes N1, Gontijo B2, Romiti R3, Santana PK4, Machado P1
1Novartis Biociências SA, Sao Paulo, Brazil, 2Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil, 3Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil, 4Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

PSY34
L13
WORK PRODUCTIVITY IN BRAZILIAN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
Lopes N1, Antonio JR2, Fabricio L3, Azulay-Abulafia L4, Dias LL5, Pertel P6
1Novartis Biociências SA, Sao Paulo, Brazil, 2Fundação Faculdade Regional de Medicina de São José do Rio Preto, Sao Jose do Rio Preto, Brazil, 3Hospital Universitário Evangélico de Curitiba,, Curitiba, Brazil, 4Instituto de Dermatologia e Estética do Rio de Janeiro (IDERJ), Rio de Janeiro, Brazil, 5ANOVA, Rio de Janeiro, Brazil, 6Novartis Biociencias SA, Sao Paulo, Brazil

PSY35
L14
TREATMENT SATISFACTION AMONG PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN BRAZIL
Lopes N1, Suarez R. M2, Sabbag CY3, Kobata CM4, Takemoto MS5, Pertel P6
1Novartis Biociências SA, Sao Paulo, Brazil, 2Hospital do Servidor Público Municipal, Sao Paulo, Brazil, 3Centro Paulista de Investigação Clínica e Serviços (CEPIC), Sao Paulo, Brazil, 4Santa Casa de Misericórdia de São Paulo, Sao Paulo, Brazil, 5ANOVA, Rio de Janeiro, Brazil, 6Novartis Biociencias SA, Sao Paulo, Brazil

PSY36
L15
IXEKIZUMAB TREATMENT LEADS TO EARLY RESOLUTION OF BOTHERSOME SYMPTOMS VERSUS USTEKINUMAB
Burge RT1, Papadimitropoulos M2, Henneges C3, Garcia EG4, Romiti R5
1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, 3Eli Lilly and Company, Bad Homburg, Germany, 4Eli Lilly and Company, Mexico City, Mexico, 5Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil

PSY37
L16
IXEKIZUMAB TREATMENT LEADS TO EARLY IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE VERSUS USTEKINUMAB
Burge RT1, Papadimitropoulos M2, Henneges C3, Garcia EG4, Romiti R5
1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Canada and Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, 3Eli Lilly and Company, Bad Homburg, Germany, 4Eli Lilly and Company, Mexico City, Mexico, 5Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil

PSY38
L17
EPIDEMIOLOGY OF PHYSICIAN-DIAGNOSED NEUROPATHIC PAIN IN BRAZIL
Udall M1, Kudel I2, Cappelleri JC3, Sadosky A1, Concialdi K2, Parsons B1, Hlavacek P1, Hopps M1, Salomon P4, DiBonaventura M5, Clark P6, Garcia JB7
1Pfizer Inc., New York, NY, USA, 2Kantar Health, New York, NY, USA, 3Pfizer Inc., Groton, CT, USA, 4Pfizer Inc., Bosques de las Lomas, Mexico, 5Ipsos Healthcare, New York, NY, USA, 6Hospital Infanti de México, Cuauhtémoc, Mexico, 7University of Maranhão, São Luís, Brazil

PSY39
L18
DELAYED BIOLOGIC SWITCHING AMONG PSORIATIC ARTHRITIS (PSA) PATIENTS MAY RESULT IN POOR HEALTH-RELATED QUALITY OF LIFE: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA
Ranza R1, Alten R2, Strand V3, Sullivan E4, Blackburn S4, Tian H5, Gandhi K5, Jugl SM6, Conaghan PG7
1Teaching Hospital Universidade Federal Uberlandia, Uberlandia, Brazil, 2Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 3Stanford University, Stanford, CA, USA, 4Adelphi Real World, Bollington, UK, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Novartis Pharma AG, Basel, Switzerland, 7University of Leeds, Leeds, UK

PSY40
M1
DELAYED BIOLOGIC SWITCHING AMONG ANKYLOSING SPONDYLITIS (AS) PATIENTS MAY RESULT IN POOR HEALTH- RELATED QUALITY OF LIFE: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA
Pereira I1, Alten R2, Conaghan PG3, Strand V4, Sullivan E5, Blackburn S5, Tian H6, Gandhi K6, Jugl SM7, Deodhar A8
1University of Southern Santa Catarina-UNISUL, Florianópolis-SC, Brazil, 2Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 3University of Leeds, Leeds, UK, 4Stanford University, Stanford, CA, USA, 5Adelphi Real World, Bollington, UK, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma AG, Basel, Switzerland, 8Oregon Health & Science University, Portland, OR, USA

PSY41
M2
PSORIATIC ARTHRITIS LIMITS PATIENTS’ ABILITY TO CONTRIBUTE TO SOCIETY AS PART OF THE WORKFORCE: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA
Scheinberg M1, Conaghan PG2, Alten R3, Sullivan E4, Blackburn S4, Tian H5, Gandhi K5, Jugl SM6, Strand V7
1Hospital AACD, Sao Paulo, Brazil, 2University of Leeds, Leeds, UK, 3Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 4Adelphi Real World, Bollington, UK, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Novartis Pharma AG, Basel, Switzerland, 7Stanford University, Stanford, CA, USA

PSY42
M3
ANKYLOSING SPONDYLITIS LIMITS PATIENTS’ ABILITY TO CONTRIBUTE TO SOCIETY AS PART OF THE WORKFORCE: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA
Deodhar A1, Conaghan PG2, Alten R3, Sullivan E4, Blackburn S4, Tian H5, Gandhi K5, Jugl SM6, Strand V7
1Oregon Health & Science University, Portland, OR, USA, 2University of Leeds, Leeds, UK, 3Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 4Adelphi Real World, Bollington, UK, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Novartis Pharma AG, Basel, Switzerland, 7Stanford University, Stanford, CA, USA

PSY43
M4
IMPACTO DEL ÍNDICE DE MASA CORPORAL EN LA SALUD AUTOPERCIBIDA: RESULTADOS DE LA ENCUESTA NACIONAL DE SALUD DE CHILE 2016-2017
Monsalves mJ1, Duran D1, Aubert J1, Rosso F2, Lopez D2, Zarate V1
1Universidad San Sebastián, Santiago, Chile, 2ministerio de salud de chile, Santiago, Chile

SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies
PSY44
M5
ELASTICIDAD PRECIO DE LA DEMANDA PARA EXPLORAR MEDIDAS IMPOSITIVAS QUE DESALIENTEN EL CONSUMO DE BEBIDAS AZUCARADAS Y CONTRIBUYAN A PREVENIR OBESIDAD Y DIABETES TIPO II.
Mosqueira NR
Knowlege and Development, Lima, Peru

PSY45
M6
TRATAMENTO CLÍNICO DE OBESIDADE ATRAVÉS DE INTERNAÇÕES CLÍNICAS EM SPA: IMPACTO ECONÔMICO DA JUDICIALIZAÇÃO
Moraes Z, Castro AP, Pegoretti Rosa B
Evidencias - Kantar Health, Campinas, Brazil

PSY46
M7
APPROPRIATE ANKYLOSING SPONDYLITIS (AS) TREATMENT IS DELAYED FOR YEARS: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA
Pinheiro M1, Strand V2, Alten R3, Conaghan PG4, Sullivan E5, Blackburn S5, Tian H6, Gandhi K6, Jugl SM7, Deodhar A8
1Federal University of Sao Paulo (Unifesp/ EPM), Sao Paulo, Brazil, 2Stanford University, Stanford, CA, USA, 3Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 4University of Leeds, Leeds, UK, 5Adelphi Real World, Bollington, UK, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharma AG, Basel, Switzerland, 8Oregon Health & Science University, Portland, OR, USA

PSY47
M8
APPROPRIATE PSORIATIC ARTHRITIS TREATMENT IS DELAYED FOR YEARS: RESULTS FROM A MULTI-NATIONAL SURVEY INCLUDING LATIN AMERICA
Azevedo VF1, Conaghan PG2, Strand V3, Sullivan E4, Blackburn S4, Tian H5, Gandhi K5, Jugl SM6, Alten R7
1Federal University of Paraná, Curitiba, Brazil, 2University of Leeds, Leeds, UK, 3Stanford University, Stanford, CA, USA, 4Adelphi Real World, Bollington, UK, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 6Novartis Pharma AG, Basel, Switzerland, 7Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany

PSY48
M9
TASAS DE HOSPITALIZACIÓN DE LOS PACIENTES CON DEFECTOS DE LA COAGULACIÓN (DEMANDA Y PROFILAXIS) EN UNA ASEGURADORA COLOMBIANA
Romero Prada ME1, Roa Cardenas NC2, Huerfano LM1, Cruz AM3, Barrios E4, Marino C5
1Fundación Salutia, Bogotá, Colombia, 2Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia, 3Coomeva EPS, Cali, Colombia, 4Coomeva Group, Cali, Colombia, 5Coomeva, Bogotá, Colombia

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.